PDF herunterladen
Neuropediatrics 2000; 31(5): 227-239
DOI: 10.1055/s-2000-9236
The Peter Emil Becker Memorial Lecture 1999

Georg Thieme Verlag Stuttgart · New York

X-Linked Adrenoleukodystrophy: Overview and Prognosis as a Function of Age and Brain Magnetic Resonance Imaging Abnormality. A Study Involving 372 Patients

H. W. Moser1 , D. J. Loes2 , E. R. Melhem3 , G. V. Raymond1 , Lena Bezman1 , Christiane S. Cox1 , Shou-en Lu4
  • 1 Kennedy Krieger Institute and Department of Neurology, Johns Hopkins Medical Institutions, Baltimore, USA
  • 2 Suburban Radiologic Consultants Ltd., Minneapolis, USA
  • 3 Department of Radiology and Radiological Sciences, The Johns Hopkins Medical Institutions, Baltimore, USA
  • 4 Departments of Biostatistics, School of Hygiene and Public Health, Johns Hopkins University, Baltimore, USA
Weitere Informationen

Publikationsverlauf

Publikationsdatum:
31. Dezember 2000 (online)

    Lizenzen und Reprints

The phenotypic expression of X-linked adrenoleukodystrophy (X-ALD) ranges from the rapidly progressive childhood cerebral form to the milder adrenomyeloneuropathy (AMN) in adults. It is not possible to predict phenotype by mutation analysis or biochemical assays. This study reports on 372 patients ranging in age from less than 3 years to adulthood, who have been followed at the Kennedy Krieger Institute. With the aim of determining whether a method could be developed to predict clinical course by analysis of data available at time of first contact, the patients were subdivided into 18 subgroups on the basis of age and the extent of brain magnetic resonance (MRI) abnormality utilizing the MRI scoring system devised by Loes et al. Scores to grade degree of neurologic and neuropsychologic impairment were also developed. There was strong correlation between MRI and the neurology and neuropsychology scores at baseline. Information based exclusively on age and MRI score at time of first contact was highly predictive of future clinical course and should aid the evaluation of the effects of bone marrow transplantation and the selection of patients for this procedure, as well as the evaluation of other therapies that may be developed in the future.

Key words

Adrenoleukodystrophy - Therapy - Bone marrow transplant - Magnetic resonance imaging - Magnetic resonance spectroscopy - Prognosis - Phenotypes - Natural history

References

  • 1 Aubourg P. X-Linked Adrenoleukodystrophy. Handbook of Clinical Neurology. Amsterdam; Elsevier 1996
    Google Scholar
  • 2 Aubourg P, Adamsbaum C, Lavallard-Rousseau M C, Rocchiccioli F, Cartier N, Jambaque I. et al . A two-year trial of oleic and erucic acids (“Lorenzo's oil”) as treatment for adrenomyeloneuropathy.  N Engl J Med. 1993;  329 745-752
    CrossrefPubMedGoogle Scholar
  • 3 Aubourg P, Blanche S, Jambaque I, Rocchiccioli F, Kalifa G, Naud-Saudreau C. et al . Reversal of early neurologic and neuroradiologic manifestations of X-linked adrenoleukodystrophy by bone marrow transplantation.  N Engl J Med. 1990;  322 1860-1866
    CrossrefPubMedGoogle Scholar
  • 4 Benton A L, Hamsher K, Varney N, Spreen O. Judgement of Line Orientation. Contributions to Neuropsychological Assessment. New York; Oxford University Press 1983
    Google Scholar
  • 5 Benton A L, Hamsher K, Varney N, Spreen O. Contributions to Neuropsychological Assessment. New York; Oxford University Press 1983
    Google Scholar
  • 6 Bezman L, Moser H W. Incidence of X-linked adrenoleukodystrophy and the relative frequency of its phenotypes.  Am J Med Genet. 1998;  76 415-419
    CrossrefPubMedGoogle Scholar
  • 7 Boehm C D, Cutting G R, Lachtermacher M B, Moser H W, Chong S S. Accurate DNA-based diagnostic and carrier testing for X-linked adrenoleukodystrophy.  Mol Genet Metab. 1999;  66 128-136
    CrossrefPubMedGoogle Scholar
  • 8 Boles D J, Craft D A, Padgett D A, Loria R M, Rizzo W B. Clinical variation in X-linked adrenoleukodystrophy: fatty acid and lipid metabolism in cultured fibroblasts.  Biochem Med Metab Biol. 1991;  45 74-91
    CrossrefPubMedGoogle Scholar
  • 9 Braiterman L T, Watkins P A, Moser A B, Smith K D. Peroxisomal very long chain fatty acid beta-oxidation activity is determined by the level of adrenoleukodystrophy protein (ALDP) expression.  Mol Genet Metab. 1999;  66 91-99
    CrossrefPubMedGoogle Scholar
  • 10 Braiterman L T, Zheng S, Watkins P A, Geraghty M T, Johnson G, McGuinness M C. et al . Suppression of peroxisomal membrane protein defects by peroxisomal ATP binding cassette (ABC) proteins.  Hum Mol Genet. 1998;  7 239-247
    CrossrefPubMedGoogle Scholar
  • 11 Bushke H. Selective reminding for analysis of memory and learning.  Journal of Verbal Learning and Behavior. 1973;  12 543-550
    PubMedGoogle Scholar
  • 12 Cartier N, Lopez J, Moullier P, Rocchiccioli F, Rolland M O, Jorge P. et al . Retroviral-mediated gene transfer corrects very-long-chain fatty acid metabolism in adrenoleukodystrophy fibroblasts.  Proc Natl Acad Sci USA. 1995;  92 1674-1678
    PubMedGoogle Scholar
  • 13 Confort-Gouny S, Vion-Dury J, Chabrol B, Nicoli F, Cozzone P J. Localised proton magnetic resonance spectroscopy in X-linked adrenoleukodystrophy.  Neuroradiology. 1995;  37 568-575
    PubMedGoogle Scholar
  • 14 Costakos D, Abramson R K, Edwards J G, Rizzo W B, Best R G. Attitudes toward presymptomatic testing and prenatal diagnosis for adrenoleukodystrophy among affected families.  Am J Med Genet. 1991;  1 295-300
    PubMedGoogle Scholar
  • 15 Delis D C, Kramer J H, Kaplan E, Ober B A. California Verbal Learning Test: Child Version. San Antonio, TX; The Psychological Corporation 1987
    Google Scholar
  • 16 Dodd A, Rowland S A, Hawkes S L, Kennedy M A, Love D R. Mutations in the adrenoleukodystrophy gene.  Hum Mutat. 1997;  9 500-511
    CrossrefPubMedGoogle Scholar
  • 17 Dubois-Dalcq M, Feigenbaum V, Aubourg P. The neurobiology of X-linked adrenoleukodystrophy, a demyelinating peroxisomal disorder.  Trends Neurosci. 1999;  22 4-12
    CrossrefPubMedGoogle Scholar
  • 18 Dunn L M, Dunn L M. Peabody Picture Vocabulary Test - Revised. Circle Pines, MN; American Guidance Service 1981
    Google Scholar
  • 19 Forss-Petter S, Werner H, Berger J, Lassmann H, Molzer B, Schwab M H. et al . Targeted inactivation of the X-linked adrenoleukodystrophy gene in mice.  J Neurosci Res. 1997;  50 829-843
    CrossrefPubMedGoogle Scholar
  • 20 Gartner J, Braun A, Holzinger A, Roerig P, Lenard H G, Roscher A A. Clinical and genetic aspects of X-linked adrenoleukodystrophy.  Neuropediatrics. 1998;  29 3-13
    PubMedGoogle Scholar
  • 21 Higgins C F. ABC transporters: From microorganisms to man.  Annu Rev Cell Biol. 1992;  8 67-113
    CrossrefPubMedGoogle Scholar
  • 22 Igarashi M, Schaumburg H H, Powers J, Kishmoto Y, Kolodny E, Suzuki K. Fatty acid abnormality in adrenoleukodystrophy.  J Neurochem. 1976;  26 851-860
    CrossrefPubMedGoogle Scholar
  • 23 Kaplan P W, Tusa R J, Shankroff J, Heller J, Moser H W. Visual evoked potentials in adrenoleukodystrophy: a trial with glycerol trioleate and Lorenzo oil.  Ann Neurol. 1993;  34 169-174
    CrossrefPubMedGoogle Scholar
  • 24 Kaufman A S, Kaufman N L. KABC Kaufman Assessment Battery for Children. Circle Pines, MN; American Guidance Service 1983
    Google Scholar
  • 25 Kemp S, Wei H M, Lu J F, Braiterman L T, McGuinness M C, Moser A B. et al . Gene redundancy and pharmacological gene therapy: implications for X-linked adrenoleukodystrophy.  Nat Med. 1998;  4 1261-1268
    PubMedGoogle Scholar
  • 26 Kobayashi T, Shinnoh N, Kondo A, Yamada T. Adrenoleukodystrophy protein-deficient mice represent abnormality of very long chain fatty acid metabolism.  Biochem Biophys Res Commun. 1997;  232 631-636
    CrossrefPubMedGoogle Scholar
  • 27 Kok F, Neumann S, Sarde C O, Zheng S, Wu K H, Wei H M. et al . Mutational analysis of patients with X-linked adrenoleukodystrophy.  Hum Mutat. 1995;  6 104-115
    CrossrefPubMedGoogle Scholar
  • 28 Korenke G C, Christen H J, Kruse B, Hunneman D H, Hanefeld F. Progression of X-linked adrenoleukodystrophy under interferon-beta therapy.  J Inherit Metab Dis. 1997;  20 59-66
    CrossrefPubMedGoogle Scholar
  • 29 Korenke G C, Pouwels P JW, Frahm J, Hunneman D H, Stoeckler S, Krasemann E. et al . Arrested cerebral adrenoleukodystrophy: A clinical and proton MRS study in 3 patients.  Pediatr Neurol. 1996;  15 103-107
    CrossrefPubMedGoogle Scholar
  • 30 Krasemann E W, Meier V, Korenke G C, Hunneman D H, Hanefeld F. Identification of mutations in the ALD-gene of 20 families with adrenoleukodystrophy/adrenomyeloneuropathy.  Hum Genet. 1996;  97 194-197
    PubMedGoogle Scholar
  • 31 Krivit W, Lockman L A, Watkins P A, Hirsch J, Shapiro E G. The future for treatment by bone marrow transplantation for adrenoleukodystrophy, metachromatic leukodystrophy, globoid cell leukodystrophy and Hurler syndrome.  J Inherit Metab Dis. 1995;  18 398-412
    CrossrefPubMedGoogle Scholar
  • 32 Krivit W, Peters C, Shapiro E G. Bone marrow transplantation as effective treatment of central nervous system disease in globoid leukodystrophy, metachromatic leukodystrophy, adrenoleukodystrophy, manosidosis, fucosidosis, aspartylglutaminuria, Hurler Maroteaux-Lamy and Sly syndromes, and Gaucher disease type III.  Curr Opin Neurol. 1999;  12 167-176
    CrossrefPubMedGoogle Scholar
  • 33 Krivit W, Shapiro E, Lockman L, Torres F, Stillman A E, Moser A. et al .Recommendations for treatment of childhood cerebral form of adrenoleukodystrophy. Hobbs JR, Riches PG Correction of Certain Genetic Diseases by Transplantation. London; COGENT Trust 1992: 38-49
    Google Scholar
  • 34 Kruse B, Barker P B, van Zijl P C, Duyn J H, Moonen C T, Moser H W. Multislice proton magnetic resonance spectroscopic imaging in X-linked adrenoleukodystrophy.  Ann Neurol. 1994;  36 595-608
    CrossrefPubMedGoogle Scholar
  • 35 Kumar A J, Rosenbaum A E, Naidu S, Wener L, Citrin C M, Lindenberg R. et al . Adrenoleukodystrophy: correlating MR imaging with CT.  Radiology. 1987;  165 497-504
    PubMedGoogle Scholar
  • 36 Ladenson P W. Adrenoleukodystrophy.  JAMA. 1989;  262 1504-1506
    CrossrefPubMedGoogle Scholar
  • 37 Lazo O, Contreras M, Hashmi M, Stanley W, Irazu C, Singh I. Peroxisomal lignoceroyl-CoA ligase deficiency in childhood adrenoleukodystrophy and adrenomyeloneuropathy.  Proc Natl Acad Sci USA. 1988;  85 7647-7651
    PubMedGoogle Scholar
  • 38 Ligtenberg M J, Kemp S, Sarde C O, van Geel B M, Kleijer W J, Barth P G. et al . Spectrum of mutations in the gene encoding the adrenoleukodystrophy protein.  Am J Hum Genet. 1995;  56 44-50
    PubMedGoogle Scholar
  • 39 Loes D J, Hite S, Moser H, Stillman A E, Shapiro E, Lockman L. et al . Adrenoleukodystrophy: a scoring method for brain MR observations.  Am J Neuroradiol. 1994;  15 1761-1766
    PubMedGoogle Scholar
  • 40 Lombard-Platet G, Savary S, Sarde C O, Mandel J L, Chimini G. A close relative of the adrenoleukodystrophy (ALD) gene codes for a peroxisomal protein with a specific expression pattern.  Proc Natl Acad Sci USA. 1996;  93 1265-1269
    CrossrefPubMedGoogle Scholar
  • 41 Lu J F, Lawler A M, Watkins P A, Powers J M, Moser A B, Moser H W. et al . A mouse model for X-linked adrenoleukodystrophy.  Proc Natl Acad Sci USA. 1997;  94 9366-9371
    CrossrefPubMedGoogle Scholar
  • 42 Maestri N E, Beaty T H. Predictions of a 2-locus model for disease heterogeneity: application to adrenoleukodystrophy.  Am J Med Genet. 1992;  44 576-582
    CrossrefPubMedGoogle Scholar
  • 43 Maier E M, Roscher A A, Kammerer S, Mehnert K, Conzelmann E, Holzinger A. Prenatal diagnosis of X-linked adrenoleukodystrophy combining biochemical, immunocytochemical and DNA analyses.  Prenat Diagn. 1999;  19 364-368
    CrossrefPubMedGoogle Scholar
  • 44 Malm G, Ringden O, Anvret M, von Dobeln U, Hagenfeldt L, Isberg B. et al . Treatment of adrenoleukodystrophy with bone marrow transplantation.  Acta Paediatr. 1997;  86 484-492
    PubMedGoogle Scholar
  • 45 McCarthy D. McCarthy Scales of Children's Abilities. San Antonio; The Psychological Corporation 1972
    Google Scholar
  • 46 Melhem E R, Breiter S N, Ulug A M, Raymond G V, Moser H W. Improved tissue characterization in adrenoleukodystrophy using magnetization transfer imaging.  Am J Roentgenol. 1996;  166 689-695
    PubMedGoogle Scholar
  • 47 Melhem E R, Loes D J, Georgiades C S, Raymond G V, Moser H W. X-linked adrenoleukodystrophy: the role of contrast-enhanced MR imaging in predicting disease progression.  Am J Neuroradiol. 2000;  21 839-844
    PubMedGoogle Scholar
  • 48 Migeon B R, Moser H W, Moser A B, Axelman J, Sillence D, Norum R A. Adrenoleukodystrophy: evidence for X linkage, inactivation, and selection favoring the mutant allele in heterozygous cells.  Proc Natl Acad Sci USA. 1981;  78 5066-5070
    PubMedGoogle Scholar
  • 49 Moser A B, Kreiter N, Bezman L, Lu S, Raymond G V, Naidu S. et al . Plasma very long chain fatty acids in 3000 peroxisome disease patients and 29, 000 controls.  Ann Neurol. 1999;  45 100-110
    CrossrefPubMedGoogle Scholar
  • 50 Moser A B, Moser H W. The prenatal diagnosis of X-linked adrenoleukodystrophy.  Prenat Diagn. 1999;  19 46-48
    CrossrefPubMedGoogle Scholar
  • 51 Moser H W. Adrenoleukodystrophy: phenotype, genetics, pathogenesis and therapy.  Brain. 1997;  120 1485-1508
    CrossrefPubMedGoogle Scholar
  • 52 Moser H W, Bergin A, Naidu S, Ladenson P W. Adrenoleukodystrophy.  Endocrinol Metab Clin North Am. 1991;  20 297-318
    PubMedGoogle Scholar
  • 53 Moser H W, Borel J. Dietary management of X-linked adrenoleukodystrophy.  Annu Rev Nutr. 1995;  15 379-397
    CrossrefPubMedGoogle Scholar
  • 54 Moser H W, Tutschka P J, Brown F R, Moser A E, Yeager A M, Singh I. et al . Bone marrow transplant in adrenoleukodystrophy.  Neurology. 1984;  34 1410-1417
    PubMedGoogle Scholar
  • 55 Mosser J, Douar A M, Sarde C O, Kioschis P, Feil R, Moser H. et al . Putative X-linked adrenoleukodystrophy gene shares unexpected homology with ABC transporters.  Nature. 1993;  361 726-730
    CrossrefPubMedGoogle Scholar
  • 56 Mosser J, Lutz Y, Stoeckel M E, Sarde C O, Kretz C, Douar A M. et al . The gene responsible for adrenoleukodystrophy encodes a peroxisomal membrane protein.  Hum Mol Genet. 1994;  3 265-271
    CrossrefPubMedGoogle Scholar
  • 57 Naidu S, Bresnan M J, Griffin D, O'Toole S, Moser H W. Childhood adrenoleukodystrophy. Failure of intensive immunosuppression to arrest neurologic progression.  Arch Neurol. 1988;  45 846-848
    CrossrefPubMedGoogle Scholar
  • 58 Pai G S, Khan M, Barbosa E, Key L, Craver J R, Cure J K. et al . Lovastatin therapy for X-linked adrenoleukodystrophy: Clinical and biochemical observations on twelve patients.  Mol Genet Metab. 2000;  69 312-322
    CrossrefPubMedGoogle Scholar
  • 59 Poulos A, Gibson R, Sharp P, Beckman K, Grattan-Smith P. Very long chain fatty acids in X-linked adrenoleukodystrophy brain after treatment with Lorenzo's oil.  Ann Neurol. 1994;  36 741-746
    CrossrefPubMedGoogle Scholar
  • 60 Pouwels P J, Kruse B, Korenke G C, Mao X, Hanefeld F A, Frahm J. Quantitative proton magnetic resonance spectroscopy of childhood adrenoleukodystrophy.  Neuropediatrics. 1998;  29 254-264
    PubMedGoogle Scholar
  • 61 Powers J M, DeCiero D P, Ito M, Moser A B, Moser H W. Adrenomyeloneuropathy: a neuropathologic review featuring its noninflammatory myelopathy.  J Neuropathol Exp Neurol. 2000;  59 89-102
    PubMedGoogle Scholar
  • 62 Powers J M, Liu Y, Moser A B, Moser H W. The inflammatory myelinopathy of adreno-leukodystrophy: cells, effector molecules, and pathogenetic implications.  J Neuropathol Exp Neurol. 1992;  51 630-643
    CrossrefPubMedGoogle Scholar
  • 63 Rajanayagam V, Grad J, Krivit W, Loes D J, Lockman L, Shapiro E. et al . Proton MR spectroscopy of childhood adrenoleukodystrophy.  Am J Neuroradiol. 1996;  17 1013-1024
    PubMedGoogle Scholar
  • 64 Rasmussen M, Moser A B, Borel J, Khangoora S, Moser H W. Brain, liver, and adipose tissue erucic and very long chain fatty acid levels in adrenoleukodystrophy patients treated with glyceryl trierucate and trioleate oils (Lorenzo's oil).  Neurochem Res. 1994;  19 1073-1082
    CrossrefPubMedGoogle Scholar
  • 65 Raven J. Raven Progressive Matrices - Research Supplement #3. San Antonio; The Psychological Corporation 1986
    Google Scholar
  • 66 Rey A. L'examen psychologique dans les cas d'encéphalopatie traumatique.  Archives De Psychologie. 1941;  28 268-345
    PubMedGoogle Scholar
  • 67 Rizzo W B. Lorenzo's oil - hope and disappointment [editorial].  N Engl J Med. 1993;  329 801-802
    CrossrefPubMedGoogle Scholar
  • 68 Rizzo W B, Leshner R T, Odone A, Dammann A L, Craft D A, Jensen M E. et al . Dietary erucic acid therapy for X-linked adrenoleukodystrophy.  Neurology. 1989;  39 1415-1422
    PubMedGoogle Scholar
  • 69 Ruiz M, Coll M J, Pampols T, Giros M. ALDP expression in fetal cells and its application in prenatal diagnosis of X-linked adrenoleukodystrophy.  Prenat Diagn. 1997;  17 651-656
    CrossrefPubMedGoogle Scholar
  • 70 Schaumburg H H, Powers J M, Raine C S, Suzuki K, Richardson E P. Adrenoleukodystrophy. A clinical and pathological study of 17 cases.  Arch Neurol. 1975;  32 577-591
    PubMedGoogle Scholar
  • 71 Shapiro E, Krivit W, Lockman L, Jambaque I, Peters C, Cowan M. et al . Long-term beneficial effect of bone marrow transplantation for childhood onset cerebral X-linked adrenoleukodystrophy.  Lancet. 2000;  356 713-718
    CrossrefPubMedGoogle Scholar
  • 72 Shapiro E G, Klein K A. Dementia in childhood: Issues in neuropsychological assessment with application to the natural history and treatment of degenerative storage diseases. Tramontana MG, Hooer SR Advances in Child Neuropsychology. New York; Springer-Verlag 1994: 119-171
    Google Scholar
  • 73 Shapiro E G, Lockman L A, Balthazor M, Krivit W. Neuropsychological outcomes of several storage diseases with and without bone marrow transplantation.  J Inherit Metab Dis. 1995;  18 413-429
    CrossrefPubMedGoogle Scholar
  • 74 Singh I, Moser A E, Goldfischer S, Moser H W. Lignoceric acid is oxidized in the peroxisome: implications for the Zellweger cerebro-hepato-renal syndrome and adrenoleukodystrophy.  Proc Natl Acad Sci USA. 1984;  81 4203-4207
    PubMedGoogle Scholar
  • 75 Singh I, Pahan K, Khan M. Lovastatin and sodium phenylacetate normalize the levels of very long chain fatty acids in skin fibroblasts of X-adrenoleukodystrophy.  FEBS Lett. 1998;  426 342-346
    CrossrefPubMedGoogle Scholar
  • 76 Smith K D, Kemp S, Braiterman L T, Lu J F, Wei H M, Geraghty M. et al . X-linked adrenoleukodystrophy: genes, mutations, and phenotypes.  Neurochem Res. 1999;  24 521-535
    CrossrefPubMedGoogle Scholar
  • 77 Smith K D, Sack G, Beaty T, Bergin A, Naidu S, Moser A. et al . A genetic basis for the multiple phenotypes of X-linked adrenoleukodystrophy.  Am J Hum Genet. 1991;  49 864 a
    PubMedGoogle Scholar
  • 78 Spreen O, Strauss E. A Compendium of Neuropsychological Tests. New York, NY; Oxford University Press 1991
    Google Scholar
  • 79 Stanislaus R, Pahan K, Singh A K, Singh I. Amelioration of experimental allergic encephalomyelitis in Lewis rats by lovastatin.  Neurosci Lett. 1999;  269 71-74
    CrossrefPubMedGoogle Scholar
  • 80 Steinberg S J, Kemp S, Braiterman L T, Watkins P A. Role of very-long-chain acyl-coenzyme A synthetase in X-linked adrenoleukodystrophy.  Ann Neurol. 1999;  46 409-412
    CrossrefPubMedGoogle Scholar
  • 81 Steinberg S J, Wang S J, McGuinness M C, Watkins P A. Human liver-specific very-long-chain acyl-coenzyme A synthetase: cDNA cloning and characterization of a second enzymatically active protein.  Mol Genet Metab. 1999;  68 32-42
    CrossrefPubMedGoogle Scholar
  • 82 Takano H, Koike R, Onodera O, Sasaki R, Tsuji S. Mutational analysis and genotype-phenotype correlation of 29 unrelated Japanese patients with X-linked adrenoleukodystrophy.  Arch Neurol. 1999;  56 295-300
    CrossrefPubMedGoogle Scholar
  • 83 Tourbah A, Stievenart J L, Iba-Zizen M T, Lubetzki C, Baumann N, Eymard B. et al . Localized proton magnetic resonance spectroscopy in patients with adult adrenoleukodystrophy. Increase of choline compounds in normal appearing white matter.  Arch Neurol. 1997;  54 586-592
    PubMedGoogle Scholar
  • 84 Tzika A A, Ball W S, Vigneron D B, Dunn R S, Kirks D R. Clinical proton MR spectroscopy of neurodegenerative disease in childhood.  Am J Neuroradiol. 1993;  14 1267-1281
    PubMedGoogle Scholar
  • 85 Uchiyama A, Aoyama T, Kamijo K, Uchida Y, Kondo N, Orii T. et al . Molecular cloning of cDNA encoding rat very long-chain acyl-CoA synthetase.  J Biol Chem. 1996;  271 30 360-30 365
    PubMedGoogle Scholar
  • 86 van Geel B M, Assies J, Haverkort E B, Koelman J H, Verbeeten B, Wanders R J. et al . Progression of abnormalities in adrenomyeloneuropathy and neurologically asymptomatic X-linked adrenoleukodystrophy despite treatment with “Lorenzo's oil”.  J Neurol Neurosurg Psychiatry. 1999;  67 290-299
    CrossrefPubMedGoogle Scholar
  • 87 van Geel B M, Assies J, Wanders R J, Barth P G. X linked adrenoleukodystrophy: clinical presentation, diagnosis, and therapy.  J Neurol Neurosurg Psychiatry. 1997;  63 4-14
    CrossrefPubMedGoogle Scholar
  • 88 Wechsler D. Wechsler Preschool and Primary Scale of Intelligence - Revised (WPPSI-R). San Antonio; The Psychological Corporation 1989
    Google Scholar
  • 89 Wechsler D. Wechsler Intelligence Scale for Children Third Edition (WISC III). San Antonio; The Psychological Corporation 1991
    Google Scholar
  • 90 Woodcock R W, Mather N. Woodcock Johnson Psychoeducational Battery Tests of Achievement - Revised. Allen, TX; DLM Teaching Resources 1972
    Google Scholar
  • 91 Zinkham W H, Kickler T, Borel J, Moser H W. Lorenzo's oil and thrombocytopenia in patients with adrenoleukodystrophy [letter].  N Engl J Med. 1993;  328 1126-1127
    CrossrefPubMedGoogle Scholar

M. D. Hugo W. Moser

Kennedy Krieger Institute

707 North Broadway

Baltimore, MD 21205

USA

      >